TD Waterhouse Canada
RXRX icon

TD Waterhouse Canada’s Recursion Pharmaceuticals RXRX Stock Holding History

TD Waterhouse Canada’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.8K Sell
20,331
-17,800
-47% -$59.3K ﹤0.01% 1312
2026
Q1 		$116K Sell
38,131
-200
-0.5% -$773 ﹤0.01% 1158
2025
Q4 		$156K Buy
38,331
+32,700
+581% +$162K ﹤0.01% 941
2025
Q3 		$28.7K Hold
5,631
– – ﹤0.01% 1315
2025
Q2 		$28.8K Buy
5,631
+2,200
+64% +$10.8K ﹤0.01% 1247
2025
Q1 		$17.4K Buy
3,431
+3,000
+696% +$21.9K ﹤0.01% 1290
2024
Q4 		$2.91K Buy
431
+231
+116% +$1.55K ﹤0.01% 1648
2024
Q3 		$1.24K Buy
200
+100
+100% +$717 ﹤0.01% 1684
2024
Q2 		$745 Hold
100
– – ﹤0.01% 1745
2024
Q1 		$875 Hold
100
– – ﹤0.01% 1738
2023
Q4 		$1.11K Hold
100
– – ﹤0.01% 1550
2023
Q3 		$717 Buy
+100
New +$998 ﹤0.01% 1575

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TD Waterhouse Canada's RXRX Position: Q2 2026 in Review

TD Waterhouse Canada reduced its Recursion Pharmaceuticals (RXRX) stake by 47% in Q2 2026, selling an estimated $59.3K and leaving 20,331 shares worth $74.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

TD Waterhouse Canada first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $156K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • TD Waterhouse Canada held 20,331 shares of Recursion Pharmaceuticals worth $74.8K as of Q2 2026.
  • TD Waterhouse Canada sold 17,800 Recursion Pharmaceuticals shares in Q2 2026, an estimated $59.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1312 holding.
  • TD Waterhouse Canada first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • TD Waterhouse Canada's Recursion Pharmaceuticals position peaked at $156K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.